Activation of cannabinoid receptors, which represents a therapeutic approach useful to control the progression of central neuroinflammation in EAE mice and MS patients, also reduces the endogenous availability of the chemokine CCL5 being concomitantly beneficial to the progression of the demyelinating disorder (41, 149). The gene discussed is CCL5; the disease is demyelinating disease.